Guizhou Yibai Pharmaceutical Co (SHSE:600594) Tariff Resilience Score: 0/10 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600594 Guizhou Yibai Pharmaceutical Co Ltd SHSE:600594
54 GF Score
Price ¥3.72
GF Value ¥2.92
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guizhou Yibai Pharmaceutical Co Tariff Resilience Score?

Guizhou Yibai Pharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Guizhou Yibai Pharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Guizhou Yibai Pharmaceutical Co might have .


Guizhou Yibai Pharmaceutical Co  (SHSE:600594) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Guizhou Yibai Pharmaceutical Co Tariff Resilience Score Related Terms

SHSE:600594
54GF Score
Guizhou Yibai Pharmaceutical Co Ltd SHSE:600594
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guizhou Yibai Pharmaceutical Co (SHSE:600594) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhou Yibai Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥3.72 is trading 27.4% above its estimated GF Value™ of ¥2.92. GuruFocus considers Guizhou Yibai Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600594:

  • Tariff Resilience Score: 0
  • GF Value™: ¥2.92 vs. price of ¥3.72 (27.4% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guizhou Yibai Pharmaceutical Co Business Description

Address No. 220-1 Baiyun Avenue, Guiyang, Guizhou, CHN, 550008
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
54GF Score

Get the complete analysis for SHSE:600594

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.72
Price
¥2.92
GF Value